Two-Year Follow-Up Analysis of Telaprevir-Based Antiviral Triple Therapy for HCV Recurrence in Genotype 1 Infected Liver Graft Recipients as a First Step towards Modern HCV Therapy

Objective. The introduction of protease inhibitors telaprevir and boceprevir in 2011 had extended the antiviral treatment options especially in genotype 1 infected hepatitis C relapsers and nonresponders to interferon/ribavirin therapy. The aim of this study was to analyze the long-term treatment ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Klein, Fritz, Neuhaus, Ruth, Eurich, Dennis, Hofmann, Jörg, Bayraktar, Sandra, Pratschke, Johann, Bahra, Marcus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2016
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4852367/
https://www.ncbi.nlm.nih.gov/pubmed/27195149
http://dx.doi.org/10.1155/2016/8325467

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4852367/
https://www.ncbi.nlm.nih.gov/pubmed/27195149
http://dx.doi.org/10.1155/2016/8325467

Ejemplares similares